Cormedix Inc. 8-K Summary: Annual Meeting Results
Business Context and Reporting Period
This Form 8-K reports the results of Cormedix Inc.'s Annual Meeting of Stockholders held on October 26, 2023. The filing covers the voting outcomes for three proposals submitted to holders of common stock, Series E Preferred Stock, and Series G Preferred Stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on and approved the following proposals:
- Proposal 1: Election of Directors. All seven nominees were elected to the Board of Directors to serve until the 2024 annual meeting. Notable vote counts included:
| Nominee | For | Withheld | Broker Non-Votes |
|---|---|---|---|
| Robert Stewart | 16,175,492 | 964,409 | 21,612,075 |
| Steven Lefkowitz | 16,007,358 | 1,132,543 | 21,612,075 |
| Gregory Duncan | 15,929,357 | 1,210,544 | 21,612,075 |
| Alan W. Dunton | 15,731,113 | 1,408,788 | 21,612,075 |
| Joseph Todisco | 12,774,071 | 4,365,830 | 21,612,075 |
| Myron Kaplan | 11,246,141 | 5,893,760 | 21,612,075 |
| Janet Dillione | 10,598,504 | 6,541,397 | 21,612,075 |
- Proposal 2: Executive Compensation. The non-binding advisory vote on 2022 executive compensation was approved with 12,781,884 votes For, 4,234,480 Against, and 123,537 Abstain.
- Proposal 3: Auditor Ratification. The appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified with 37,796,427 votes For, 700,384 Against, and 255,165 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the standard disclosure of voting results.
Investor Verification Checklist
- Verify the definitive proxy statement filed on September 13, 2023, for detailed biographies of the elected directors and executive compensation specifics.
- Confirm the total number of shares outstanding and the specific voting rights attached to Series E and Series G Preferred Stock.
- Review the high number of broker non-votes (21,612,075) to understand the proportion of shares held in street name that did not receive voting instructions.
- Check subsequent filings for the official appointment of Marcum LLP and any related audit committee reports.